)
Aurora Cannabis (ACB) investor relations material
Aurora Cannabis Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 FY27 net revenue rose 9% YoY to $86.0M; record international medical cannabis revenue of $61.4M grew 44% YoY.
Adjusted EBITDA was $14.0M; continuing-operations net loss narrowed to $21.1M from $27.2M, while adjusted net income fell to $3.1M from $12.0M.
Financial highlights
Net revenue was $86.0M vs. $78.8M YoY; gross profit was $37.5M vs. $31.1M, and adjusted gross profit before fair value adjustments was $52.3M vs. $51.2M.
Adjusted EBITDA was $14.0M vs. $15.4M YoY; adjusted SG&A rose to $37.4M from $34.9M.
Operating expenses rose to $55.5M from $48.2M YoY.
Free cash flow outflow improved to $17.5M from $39.9M YoY, primarily reflecting working capital investment of $12.6M vs. $37.2M.
Outlook and guidance
The proposed Organigram transaction is expected to close in January 2027, subject to shareholder, court and regulatory approvals and customary closing conditions; a shareholder meeting is expected in December 2026.
- Strong financial results, all proposals passed, and focus shifts to global medical cannabis growth.ACB
AGM 2026 - International medical cannabis revenue rose 17% to $43.3M as net revenue fell 9% year-over-year.ACB
Q1 2027 - Record medical cannabis revenue and EBITDA, with global expansion offsetting Canadian headwinds.ACB
Q4 2026 - Medical cannabis focus and international expansion drive strong growth and industry-leading margins.ACB
TD Cowen 46th Annual Health Care Conference - Record medical cannabis revenue, high margins, and strategic exits drive growth and profitability.ACB
Q3 2026 - Record Q2 medical cannabis growth and profitability led by international markets and strong margins.ACB
Q2 2025 - All motions passed as strong financials and global expansion plans were highlighted.ACB
AGM 2024 - Record global medical cannabis revenue, free cash flow, and EBITDA growth achieved.ACB
Q1 2025 - Record adjusted EBITDA, strong medical cannabis growth, and debt-free status support positive outlook.ACB
Q4 2024
Next Aurora Cannabis earnings date
Next Aurora Cannabis earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)